From Medscape Nephrology

International Society of Nephrology (ISN): 2022 World Congress

February 24 - 27, 2022; Kuala Lumpur, Malaysia and Virtual

February 24 - 27, 2022 Kuala Lumpur, Malaysia and Virtual

ISN 2022 FDA Rejects Bardoxolone as First Alport Syndrome Agent Alport syndrome, a rare genetic disease that causes early kidney failure, continues to have no approved treatment, but advocates foresee progress in diagnosis and awareness from the failed approval attempt.
Medscape Medical News, March 15, 2022
ISN 2022 Avacopan Shows Efficacy Signal for Rare Kidney Disease, C3G Avacopan, recently FDA approved for ANCA-associated vasculitis, showed significant benefit for reducing disease chronicity in a randomized trial of 52 patients with C3 glomerulopathy.
Medscape Medical News, March 7, 2022
ISN 2022 Finerenone + SGLT2 Inhibitor of Benefit in Diabetes With CKD? Results from FIDELITY, a prespecified analysis of data from two pivotal trials of finerenone, hints of an additive benefit with SGLT2 inhibitors in patients with type 2 diabetes.
Medscape Medical News, February 28, 2022

Half of Patients in Hospital for COVID-19 Get Acute Kidney Injury Reports from two independent European case series further document the high incidence of acute kidney injury among patients hospitalized for COVID-19; lessons can be learned, says expert.
Medscape Medical News, Apr 27, 2021

Credit:
Fakrul Jamil Photography / Getty Images

Medscape Nephrology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Previous Coverage